Observational Study
Copyright ©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Oct 7, 2014; 20(37): 13582-13590
Published online Oct 7, 2014. doi: 10.3748/wjg.v20.i37.13582
Table 2 Laboratory assessments and anti-hepatitis B virus treatments administered to patients with hepatitis B virus infection, and the responses to treatment n (%)
HBV(n = 2562)HBV and HCV(n = 42)
Laboratory assessments:
HBsAg positive12195/2207 (99.5)32/35 (91.4)
HBeAg positive1971/2137 (45.4)5/34 (14.7)
HBeAb positive11056/2092 (50.4)26/32 (81.3)
HBV DNA positive11278/2286 (55.9)313/38 (34.2)
ALT abnormal944 (36.8)19 (45.2)
AST abnormal740 (28.9)16 (38.1)
AFP abnormal142/866 (16.3)4/22 (18.2)
Received antiviral treatment1490 (58.2)22 (52.4)
Latest antiviral therapies(n = 1490)(n = 22)
Interferon (IFN)109 (7.3)2 (9.1)
PEG-IFN99 (6.6)14 (63.6)
Lamivudine467 (31.3)4 (18.2)
Telbivudine238 (16.0)1 (4.5)
Adefovir dipivoxil691 (46.4)4 (18.2)
Entecavir230 (15.4)2 (9.1)
Duration of completed treatment, months, median (IQR)(n = 1309)(n = 21)
11.2 (0-187.8)7.8 (0.6-69.6)
Responses to treatment(n = 801)(n = 12)
Virological response2645 (80.5)11 (91.7)
Biochemical response3465 (58.1)5 (41.7)
Serological response4105 (13.1)2 (16.7)
Treatment status5
Sustained response65/38 (13.2)0
Virological breakthrough20/801 (2.5)0